Surrozen, Inc., a company focused on developing biological products, has recently disclosed significant stock transactions involving its director Tim Kutzkey. According to a filing with the SEC, Kutzkey acquired a total of 1,551,780 shares through private placements on October 20, 2026. This acquisition is noteworthy as it underscores Kutzkey's confidence in the company's future and reflects broader investment trends within the biological products industry.
Surrozen, Inc. is classified under the Standard Industrial Classification (SIC) code 2836, which pertains to biological products excluding diagnostic substances. The company is listed on the Nasdaq under the ticker symbol SRZN. As a smaller reporting company, Surrozen is categorized as a non-accelerated filer. The latest filing, dated October 22, 2026, is part of a series of recent disclosures from the company, including multiple Form 4 filings and a Schedule 13D/A.
The SEC filing reveals that Kutzkey's transactions included the purchase of 485,830 shares from The Column Group III, LP, 548,653 shares from The Column Group III-A, LP, and 517,241 shares from The Column Group Opportunity III, LP. Each transaction was executed at a price of $11.60 per share. Following these transactions, Kutzkey now holds a total of 1,386,122 shares directly.
In addition to the common stock acquisitions, the filing also highlights Kutzkey's involvement with derivative transactions. He acquired 728,745 Second Tranche Units, each consisting of one share of common stock and a half Series E Common Warrant, from The Column Group III, LP, and similar units from the other two groups. This indicates a strategic move to enhance his stake in the company through various financial instruments.
The implications of Kutzkey's acquisitions could affect various stakeholders, including current shareholders, potential investors, and competitors in the biological products sector. Increased ownership by a director often signals confidence in the company's direction and may influence market perceptions. Competitors may need to reassess their strategies in light of this heightened investment activity.
As for what’s next, the filing does not provide specific details on future actions or plans following these transactions. However, the increased ownership by Kutzkey may lead to further developments in Surrozen's strategic initiatives or collaborations in the biological products landscape.